Since leriglitazone exerts an anti-inflammatory effect through NF-κB modulation, we studied its effect on the neuroinflammatory landscape in Rett syndrome, noting a correction in leriglitazone-treated animals (Fig. 5A). The gene discussed is NFKB1; the disease is atypical Rett syndrome.